Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Dong-Xin Wang, MD, PhD
Peking University First Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Peking University First Hospital
Beijing, Beijing Municipality, China
- Fujian Medical University Union Hospital
Fuzhou, Fujian, China
- Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
- Xijing Hospital, Air Force Medical University
Xi'an, Shaanxi, China
- First Affilited Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
- Second Affilited Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2026
- Primary completion
- 30 Jun 2029
- Completion
- 30 Jun 2030
- Last update posted
- 12 May 2026
- Registered enrollment
- 1,160
- Registry id
- NCT07576517
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.